.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Covington
Cantor Fitzgerald
Cerilliant
Novartis
Johnson and Johnson
Queensland Health
QuintilesIMS
US Army
Harvard Business School

Generated: December 17, 2017

DrugPatentWatch Database Preview

Par Pharm Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?

PAR PHARM INC has twenty-four approved drugs.

There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.

There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-two supplementary protection certificates in eleven countries.

Summary for Par Pharm Inc

International Patents:9
US Patents:1
Tradenames:23
Ingredients:23
NDAs:24
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm IncTIZANIDINE HYDROCHLORIDEtizanidine hydrochlorideTABLET;ORAL207170-001Jan 26, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncZOLPIDEM TARTRATEzolpidem tartrateTABLET;SUBLINGUAL204229-002Sep 11, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncROSUVASTATIN CALCIUMrosuvastatin calciumTABLET;ORAL079168-002Jul 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncETHACRYNIC ACIDethacrynic acidTABLET;ORAL208501-001Jul 21, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncAMLODIPINE BESYLATE AND VALSARTANamlodipine besylate; valsartanTABLET;ORAL090011-003Mar 28, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncROSUVASTATIN CALCIUMrosuvastatin calciumTABLET;ORAL079168-004Jul 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-001Sep 26, 1996ABRXYesYes► Subscribe► Subscribe► Subscribe
Par Pharm IncPHENOXYBENZAMINE HYDROCHLORIDEphenoxybenzamine hydrochlorideCAPSULE;ORAL204522-001Jan 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncAMLODIPINE BESYLATE AND VALSARTANamlodipine besylate; valsartanTABLET;ORAL090011-004Mar 28, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm IncOLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDEamlodipine besylate; hydrochlorothiazide; olmesartan medoxomilTABLET;ORAL206137-003Oct 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm IncACCOLATEzafirlukastTABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PAR PHARM INC drugs

Drugname Dosage Strength Tradename Submissiondate
zafirlukastTablets10 mg and 20 mgACCOLATE2/29/2008

International Patent Family for Par Pharm Inc Drugs

Country Document Number Estimated Expiration
Australia2006240490► Subscribe
China101163679► Subscribe
Canada2605413► Subscribe
European Patent Office1948613► Subscribe
South Korea20080000660► Subscribe
Japan2008538560► Subscribe
World Intellectual Property Organization (WIPO)2006115626► Subscribe
Mexico2007013118► Subscribe
Japan5378788► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Par Pharm Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/008Ireland► SubscribePRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
90023-0Sweden► SubscribePRODUCT NAME: ROSUVASTATIN
C0043France► SubscribePRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106
544Luxembourg► SubscribePRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724
275Luxembourg► SubscribeCERTIFICATE TITLE: ENTECAVIR ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BARACLUDE); FIRST REGISTRATION: 20060626
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
00528Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
0625Netherlands► SubscribePRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
2015 00004Denmark► SubscribePRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Boehringer Ingelheim
Daiichi Sankyo
US Department of Justice
Federal Trade Commission
Fish and Richardson
QuintilesIMS
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot